ÂÜÀòÂÒÂ×

Barbara M. Finn is the Vice President of Regulatory Affairs and Quality Assurance at Otonomy. Barbara has over 25 years of experience in the pharmaceutical industry, with a focus on regulatory affairs and quality assurance.

Barbara began their career at Neurocrine Biosciences, where they served as Vice President of Regulatory Affairs and QA for eight years. In this role, they were responsible for regulatory interactions for all domestic and international filings, as well as providing strategic advice for all projects. Barbara also oversaw the quality assurance department, which included GMP, GCP, and GLP activities.

In 2008, they moved to Sonexa, where they served as Sr. VP of Regulatory Affairs and Quality Assurance for five years. In this role, they participated in the company management team and was responsible for regulatory interactions for all FDA and Health Canada filings. Barbara also provided strategic regulatory and drug development advice for the lead compound and oversaw the quality assurance department, medical writing, toxicology studies, and manufacturing.

Barbara has a deep understanding of the regulatory process and has been successful in navigating the complex landscape of the pharmaceutical industry. Barbara is a trusted advisor to their colleagues and an expert in their field.

Barbara M. Finn has a Bachelor of Science in Chemistry from Saint Elizabeth University.

Barbara M. Finn reports to David A. Weber, President & CEO. Some of their coworkers include Robert Michael Savel - Chief Technical Officer, Carla Da Luz Boren - General Counsel and Head of Human Resources, and Elizabeth J. Ackermann - Vice President, Clinical Development.